Comparison between ablation efficacy of 1.1 GBq and 3.7 GBq 131I for low- and intermediate-risk differentiated thyroid carcinoma

中华核医学与分子影像杂志 Pub Date : 2019-09-25 DOI:10.3760/CMA.J.ISSN.2095-2848.2019.09.004

Yuyan Jiang, Jian Tan, Guizhi Zhang, Z. Meng, Lingyun Xu, Fuhai Zhang

{"title":"Comparison between ablation efficacy of 1.1 GBq and 3.7 GBq 131I for low- and intermediate-risk differentiated thyroid carcinoma","authors":"Yuyan Jiang, Jian Tan, Guizhi Zhang, Z. Meng, Lingyun Xu, Fuhai Zhang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.004","DOIUrl":null,"url":null,"abstract":"Objective\r\nTo compare the ablation efficacy and therapy response with 1.1 GBq and 3.7 GBq 131I in postoperative patients with low- and intermediate-risk differentiated thyroid carcinoma(DTC).\r\n\r\n\r\nMethods\r\nA total of 190 patients (43 males, 147 females, age: (45.8±11.1)years) were enrolled from July 2016 to July 2017. Among them, 96 patients received 1.1 GBq 131I and 94 were given 3.7 GBq 131I. Diagnostic whole-body scan was performed 6 months after 131I ablation for treatment response evaluation, and the successful rate of 131I ablation was calculated. χ2 test or Fisher′s exact test was used for data analysis. The cut-off value of 99Tcm-pertechnetate uptake for predicting the successful rate of remnant thyroid ablation in 1.1 GBq group was determined by receiver operating characteristic (ROC) curve analysis.\r\n\r\n\r\nResults\r\nThe successful ablation rates in 1.1 GBq and 3.7 GBq groups were 79.2%(76/96) and 81.9%(77/94), respectively (χ2=0.229, P>0.05). There was no significant difference in the therapy response between the two groups (χ2=1.371, P>0.05). The successful ablation rate in 3.7 GBq group was higher than that in 1.1 GBq group for patients with stage Ⅲ (5/6 vs 1/7, P=0.029). Moreover, for patients with 5 μg/L<preablative-stimulated thyroglobulin (ps-Tg)≤10 μg/L, the ablation rate in 1.1 GBq group was lower than that in 3.7 GBq group (3/11 vs 10/13, P=0.038). ROC curve analysis showed the cut-off value of 99Tcm-pertechnetate uptake for prediction of the successful ablation rate in 1.1 GBq group was 0.061 5.\r\n\r\n\r\nConclusion\r\nThe low- and intermediate-risk DTC patients with stage Ⅲ disease, 5 μg/L<ps-Tg≤10 μg/L or higher 99Tcm-pertechnetate uptake of remnant thyroid should be given 3.7 GBq other than 1.1 GBq 131I to obtain a better ablation efficacy.\r\n\r\n\r\nKey words: \r\nThyroid neoplasms; Radiotherapy; Iodine radioisotopes; Radiotherapy dosage; Treatment outcome","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"526-531"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To compare the ablation efficacy and therapy response with 1.1 GBq and 3.7 GBq 131I in postoperative patients with low- and intermediate-risk differentiated thyroid carcinoma(DTC). Methods A total of 190 patients (43 males, 147 females, age: (45.8±11.1)years) were enrolled from July 2016 to July 2017. Among them, 96 patients received 1.1 GBq 131I and 94 were given 3.7 GBq 131I. Diagnostic whole-body scan was performed 6 months after 131I ablation for treatment response evaluation, and the successful rate of 131I ablation was calculated. χ2 test or Fisher′s exact test was used for data analysis. The cut-off value of 99Tcm-pertechnetate uptake for predicting the successful rate of remnant thyroid ablation in 1.1 GBq group was determined by receiver operating characteristic (ROC) curve analysis. Results The successful ablation rates in 1.1 GBq and 3.7 GBq groups were 79.2%(76/96) and 81.9%(77/94), respectively (χ2=0.229, P>0.05). There was no significant difference in the therapy response between the two groups (χ2=1.371, P>0.05). The successful ablation rate in 3.7 GBq group was higher than that in 1.1 GBq group for patients with stage Ⅲ (5/6 vs 1/7, P=0.029). Moreover, for patients with 5 μg/L

查看原文本刊更多论文

1.1GBq和3.7GBq131I治疗中低危分化型甲状腺癌的疗效比较

目的比较低、中危分化型甲状腺癌(DTC)术后1.1 GBq和3.7 GBq 131I消融的疗效和治疗反应。方法2016年7月至2017年7月共纳入190例患者，其中男性43例，女性147例，年龄(45.8±11.1)岁。其中96例患者接受1.1 GBq 131I治疗，94例患者接受3.7 GBq 131I治疗。131I消融后6个月行诊断性全身扫描评估治疗效果，计算131I消融成功率。采用χ2检验或Fisher精确检验进行数据分析。通过受试者工作特征(ROC)曲线分析，确定99tcm -高锝酸盐摄取预测1.1 GBq组残余甲状腺消融成功率的临界值。结果1.1 GBq组和3.7 GBq组消融成功率分别为79.2%(76/96)和81.9%(77/94)，差异有统计学意义(χ2=0.229, P < 0.05)。两组患者治疗效果比较，差异无统计学意义(χ2=1.371, P < 0.05)。3.7 GBq组Ⅲ期患者消融成功率高于1.1 GBq组(5/6 vs 1/7, P=0.029)。对于5 μg/L<术前促甲状腺球蛋白(ps-Tg)≤10 μg/L的患者，1.1 GBq组消融率低于3.7 GBq组(3/11 vs 10/13, P=0.038)。ROC曲线分析显示，1.1 GBq组99tcm -高锝酸盐摄取预测消融成功率的临界值为0.0615。结论对于疾病分期为Ⅲ、残余甲状腺5 μg/L

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华核医学与分子影像杂志核医学，分子影像

自引率

0.00%

发文量

5088

期刊介绍： Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness. Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include: -Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment -Investigative studies of heart, brain imaging and tumor positioning -Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging - Nuclear medicine education and personnel training - Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.

京公网安备 11010802042870号

Book学术文献互助群
群号：604180095